AR050626A1 - Composicion quimica y metodo para tratar desorden gastrointestinal - Google Patents

Composicion quimica y metodo para tratar desorden gastrointestinal

Info

Publication number
AR050626A1
AR050626A1 ARP050103687A ARP050103687A AR050626A1 AR 050626 A1 AR050626 A1 AR 050626A1 AR P050103687 A ARP050103687 A AR P050103687A AR P050103687 A ARP050103687 A AR P050103687A AR 050626 A1 AR050626 A1 AR 050626A1
Authority
AR
Argentina
Prior art keywords
chemical composition
gastrointestinal disorder
treat gastrointestinal
effective
subject
Prior art date
Application number
ARP050103687A
Other languages
English (en)
Spanish (es)
Inventor
Ryohei Ueno
Original Assignee
Sucampo Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35229739&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR050626(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sucampo Ag filed Critical Sucampo Ag
Publication of AR050626A1 publication Critical patent/AR050626A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/94—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
ARP050103687A 2004-09-02 2005-09-02 Composicion quimica y metodo para tratar desorden gastrointestinal AR050626A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60652104P 2004-09-02 2004-09-02
US66631705P 2005-03-30 2005-03-30
US66659305P 2005-03-31 2005-03-31

Publications (1)

Publication Number Publication Date
AR050626A1 true AR050626A1 (es) 2006-11-08

Family

ID=35229739

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050103687A AR050626A1 (es) 2004-09-02 2005-09-02 Composicion quimica y metodo para tratar desorden gastrointestinal

Country Status (16)

Country Link
US (2) US8748481B2 (cg-RX-API-DMAC7.html)
EP (1) EP1791545B1 (cg-RX-API-DMAC7.html)
JP (4) JP2008511541A (cg-RX-API-DMAC7.html)
KR (4) KR20070048221A (cg-RX-API-DMAC7.html)
CN (1) CN102885821A (cg-RX-API-DMAC7.html)
AR (1) AR050626A1 (cg-RX-API-DMAC7.html)
AU (1) AU2005278323B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0514891A (cg-RX-API-DMAC7.html)
CA (1) CA2577284A1 (cg-RX-API-DMAC7.html)
ES (1) ES2603381T3 (cg-RX-API-DMAC7.html)
IL (1) IL181332A (cg-RX-API-DMAC7.html)
MX (1) MX2007002602A (cg-RX-API-DMAC7.html)
NO (1) NO340989B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ553434A (cg-RX-API-DMAC7.html)
TW (1) TWI387454B (cg-RX-API-DMAC7.html)
WO (1) WO2006025599A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1562604E (pt) * 2002-10-23 2012-04-09 Sucampo Ag Compostos de prostaglandina para o tratamento de obesidade
EP1641462B1 (en) * 2003-07-03 2010-11-24 Sucampo AG Enteric coated composition comprising prostaglandin analogs as chloride channel opener
EP1984027B1 (en) 2006-01-24 2015-12-30 R-Tech Ueno, Ltd. Pharmaceutical composition comprising a bi-cyclic compound and method for stabilizing the bi-cyclic compound
US20090030072A1 (en) * 2007-07-03 2009-01-29 Sucampo Ag Pharmaceutical combination of opioid and prostaglandin compound
CA2870252A1 (en) * 2012-04-23 2013-10-31 Sucampo Ag Method for treating irritable bowel syndrome with diarrhea
AU2014213251B2 (en) * 2013-02-04 2017-07-20 Taisho Pharmaceutical Co., Ltd. Prophylactic or therapeutic drug for constipation
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166174A (en) 1987-01-28 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti-ulcers containing same
US5380709A (en) 1987-01-28 1995-01-10 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti ulcers containing same
US5225439A (en) 1987-01-28 1993-07-06 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti ulcers containing same
US5317032A (en) * 1987-10-02 1994-05-31 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Prostaglandin cathartic
JP4332316B2 (ja) 1999-10-15 2009-09-16 スキャンポ・アーゲー 二環式化合物組成物およびその安定化方法
US6414016B1 (en) * 2000-09-05 2002-07-02 Sucampo, A.G. Anti-constipation composition
TWI302100B (en) 2001-05-02 2008-10-21 Sucampo Ag Composition for treating drug-induced constipation
PT1389116E (pt) 2001-05-18 2008-04-11 Sucampo Ag Composição de indução catártica
BR0212233A (pt) * 2001-08-31 2004-10-05 Sucampo Ag Abridor de canal de cloreto
AR037524A1 (es) * 2001-11-14 2004-11-17 Sucampo Ag Unidad de dosificacion que comprende un analogo de prostaglandina para el tratamiento de la constipacion
US7732487B2 (en) 2001-11-19 2010-06-08 Sucampo Ag Method for treating a disease or condition responsive to opening of C1C-2 channel
KR101164838B1 (ko) * 2002-12-27 2012-07-11 수캄포 아게 복부 불쾌감 치료용 프로스타글랜딘의 유도체
EP1641462B1 (en) 2003-07-03 2010-11-24 Sucampo AG Enteric coated composition comprising prostaglandin analogs as chloride channel opener

Also Published As

Publication number Publication date
CN102885821A (zh) 2013-01-23
ES2603381T3 (es) 2017-02-27
US8748481B2 (en) 2014-06-10
TWI387454B (zh) 2013-03-01
IL181332A0 (en) 2007-07-04
NZ553434A (en) 2010-01-29
NO340989B1 (no) 2017-07-31
JP6408426B2 (ja) 2018-10-17
KR20070048221A (ko) 2007-05-08
US20060063830A1 (en) 2006-03-23
AU2005278323A1 (en) 2006-03-09
JP2008511541A (ja) 2008-04-17
BRPI0514891A (pt) 2008-06-24
KR20170003712A (ko) 2017-01-09
KR20180033310A (ko) 2018-04-02
EP1791545B1 (en) 2016-08-31
WO2006025599A1 (en) 2006-03-09
MX2007002602A (es) 2007-04-25
JP2018150354A (ja) 2018-09-27
JP2015166377A (ja) 2015-09-24
AU2005278323B2 (en) 2011-03-17
NO20071704L (no) 2007-05-31
EP1791545A1 (en) 2007-06-06
JP2013049688A (ja) 2013-03-14
US20140315994A1 (en) 2014-10-23
CA2577284A1 (en) 2006-03-09
IL181332A (en) 2015-09-24
KR20140019006A (ko) 2014-02-13
TW200612901A (en) 2006-05-01

Similar Documents

Publication Publication Date Title
AR048645A1 (es) Tratamientos para el implante ocular de efecto terapeutico prolongado
AR109605A2 (es) Método para tratar enfermedades vasculares periféricas, composición y utilización
UY28081A1 (es) Administracinn combinada de una indolinona con un agente quimioterapcutico para trastornos de proliferacinn celular
NI200800169A (es) Uso de derivados de sulfamidas heterocíclicas benzo-fusionadas para el tratamiento del dolor
UY32032A (es) "2-[1-sustituido-1h-pirazolo[3,4-d]pirimidin-4-il](io, oxi o amino)-n-(heteroaril)alcanamidas"
CR8380A (es) Metodos para preparar y utilizar compuestos novedosos de celulas madre y sus conjuntos
PH12021500006A1 (en) Methods of treatment and prevention of alzheimer's disease
MX360684B (es) Silicato de zirconio microporoso para el tratamiento de la hipercalemia.
CL2024002764A1 (es) Tratamiento de neurofibromas plexiformes asociados a neurofibromatosis tipo 1 (nf1) en pacientes pediátricos con mirdametinib
UY30158A1 (es) Uso de derivados de benzo-heteroaril sulfamida para el tratamiento del dolor
AR049844A1 (es) Memantina como tratamiento adyuvante con antipsicoticos atipicos en pacientes con esquizofrenia
EA202090564A1 (ru) Способы усиления и/или стабилизации сердечной функции у пациентов с болезнью фабри
AR050626A1 (es) Composicion quimica y metodo para tratar desorden gastrointestinal
EA202090242A1 (ru) Лечение болезни фабри у фзт-наивных и фзт-леченных пациентов
AR124479A1 (es) Métodos de monitoreo de la digoxina con el uso de vibegrón para el tratamiento de la vejiga hiperactiva
CL2021001397A1 (es) Vibegrón para el tratamiento de los síntomas de la vejiga hiperactiva
EA200700407A1 (ru) Производные хиназолина и их использования при лечении тромбоцитемии
MX2022016406A (es) Metodos para tratar el cancer o enfermedad de von-hippel lindau usando una combinacion de un inhibidor de hif-2 alpha y lenvatinib.
AR107905A2 (es) Composición química y método para tratar desorden gastrointestinal
MX2021014103A (es) Compuestos de briostatina para mejorar la inmunoterapia.
BR0108261A (pt) Uso de mirtazapina, método de tratamento de um distúrbio do sono em um indivìduo, e, kit para paciente para o tratamento de distúrbios do sono
AR117861A1 (es) Métodos de reducción de eventos cerebrovasculares en pacientes con enfermedad de fabry
MX2023013514A (es) Metodos para tratar la cistitis intersticial/sindrome de dolor en la vejiga.
PL1498119T3 (pl) Zastosowanie sprzężonych dienów kwasu linolowego do leczenia przeziębienia
PA8806001A1 (es) Nuevo uso medico de las sales de propionato de 3-(2,2,2-trimetilhidrazinio) en el tratamiento de la enfermedad cardíaca isquémica

Legal Events

Date Code Title Description
FC Refusal